Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421).

Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL III, Vogelzang NJ, Thompson IM Jr, Moinpour CM.

J Patient Rep Outcomes. 2018 Jun 13;2:27. doi: 10.1186/s41687-018-0054-5. eCollection 2017.


The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.

Haque I, Subramanian A, Huang CH, Godwin AK, Van Veldhuizen PJ, Banerjee S, Banerjee SK.

Int J Mol Sci. 2017 Dec 31;19(1). pii: E107. doi: 10.3390/ijms19010107. Review.


Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.


Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.

Huang CH, Williamson SK, Neupane P, Taylor SA, Allen A, Smart NJ, Uypeckcuat AM, Spencer S, Wick J, Smith H, Van Veldhuizen PJ, Kelly K.

Front Oncol. 2016 Jan 13;5:301. doi: 10.3389/fonc.2015.00301. eCollection 2015.


A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer.

Huang CH, Wick JA, Sittampalam GS, Nirmalanandhan VS, Ganti AK, Neupane PC, Williamson SK, Godwin AK, Schmitt S, Smart NJ, Spencer S, Van Veldhuizen PJ.

Front Oncol. 2014 Oct 14;4:271. doi: 10.3389/fonc.2014.00271. eCollection 2014.


Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.

Dusing RW, Peng W, Lai SM, Grado GL, Holzbeierlein JM, Thrasher JB, Hill J, Van Veldhuizen PJ.

Clin Nucl Med. 2014 Sep;39(9):777-83. doi: 10.1097/RLU.0000000000000516.


Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.


Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.

Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.


NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.

Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S, Srivastava RK.

Oncogenesis. 2013 Apr 8;2:e42. doi: 10.1038/oncsis.2013.5.


NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200.

Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK, Shankar S.

Neuro Oncol. 2013 Jun;15(6):691-706. doi: 10.1093/neuonc/not011. Epub 2013 Mar 12.


A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model.

Kambhampati S, Rajewski RA, Tanol M, Haque I, Das A, Banerjee S, Jha S, Burns D, Borrego-Diaz E, Van Veldhuizen PJ, Banerjee SK.

Mol Cancer Ther. 2013 Mar;12(3):255-63. doi: 10.1158/1535-7163.MCT-12-0777. Epub 2013 Jan 3.


Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.

Smith DC, Tangen CM, Van Veldhuizen PJ Jr, Harrer GW, Golshayan A, Mills GM, Vogelzang NJ, Thompson IM, Hussain MH.

Urology. 2011 May;77(5):1172-6. doi: 10.1016/j.urology.2010.12.043. Epub 2011 Feb 21.


Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis.

Haque I, Mehta S, Majumder M, Dhar K, De A, McGregor D, Van Veldhuizen PJ, Banerjee SK, Banerjee S.

Mol Cancer. 2011 Jan 13;10:8. doi: 10.1186/1476-4598-10-8.


Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.

Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K.

J Thorac Oncol. 2011 Feb;6(2):372-7. doi: 10.1097/JTO.0b013e318200f9ad.


Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1.

Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK, Banerjee S.

Mol Cancer. 2010 Aug 5;9:209. doi: 10.1186/1476-4598-9-209.


Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH.

Clin Cancer Res. 2010 Jun 1;16(11):3028-34. doi: 10.1158/1078-0432.CCR-09-3122. Epub 2010 May 18.


Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.

Hashmi MH, Van Veldhuizen PJ.

Expert Opin Biol Ther. 2010 May;10(5):807-17. doi: 10.1517/14712598.2010.480971. Review.


Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.

Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED.

BJU Int. 2010 Feb;105(3):317-21. doi: 10.1111/j.1464-410X.2009.08799.x. Epub 2009 Nov 2.


S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.

Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ Jr, Budd GT, Abbruzzese JL, Macdonald JS.

Am J Clin Oncol. 2010 Apr;33(2):117-20. doi: 10.1097/COC.0b013e318199fb84.


Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.

J Urol. 2009 Nov;182(5):2257-64. doi: 10.1016/j.juro.2009.07.046. Epub 2009 Sep 16.


A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE.

Am J Clin Oncol. 2009 Oct;32(5):453-9.


Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED.

Clin Genitourin Cancer. 2008 Sep;6(2):103-9. doi: 10.3816/CGC.2008.n.016.


VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.

Banerjee S, Mehta S, Haque I, Sengupta K, Dhar K, Kambhampati S, Van Veldhuizen PJ, Banerjee SK.

Biochemistry. 2008 Mar 18;47(11):3345-51. doi: 10.1021/bi8000352. Epub 2008 Feb 20.


2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2-methoxyestradiol-induced inhibition of cell growth.

Van Veldhuizen PJ, Ray G, Banerjee S, Dhar G, Kambhampati S, Dhar A, Banerjee SK.

Int J Cancer. 2008 Feb 1;122(3):567-71.


Effects of soy phytoestrogens on the prostate.

Goetzl MA, Van Veldhuizen PJ, Thrasher JB.

Prostate Cancer Prostatic Dis. 2007;10(3):216-23. Epub 2007 Feb 20. Review.


The validity of the dissociative disorders.

Van Veldhuizen PJ.

Psychother Psychosom. 2007;76(1):58-9; author reply 59-60. No abstract available.


Dose effect of soy supplementation in prostate cancer: a pilot study.

van Veldhuizen PJ, Thrasher JB, Ray G, Cherian R, Ward J, Holzbeierlein J, Gutow S, Banerjee SK.

Oncol Rep. 2006 Dec;16(6):1221-4.


Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways.

Ray G, Dhar G, Van Veldhuizen PJ, Banerjee S, Saxena NK, Sengupta K, Banerjee SK.

Biochemistry. 2006 Mar 21;45(11):3703-13.


A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

Van Veldhuizen PJ, Faulkner JR, Lara PN Jr, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED; Southwest Oncology Group.

Cancer Chemother Pharmacol. 2005 Jul;56(1):39-45. Epub 2005 Mar 25.


Growth factors involved in prostate carcinogenesis.

Kambhampati S, Ray G, Sengupta K, Reddy VP, Banerjee SK, Van Veldhuizen PJ.

Front Biosci. 2005 May 1;10:1355-67. Review.


Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.

Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S.

Cancer. 2003 Nov 1;98(9):1855-62.


Psychiatrists' attitudes toward dissociative disorders diagnoses.

van Veldhuizen PJ.

Am J Psychiatry. 2000 Jul;157(7):1180-2. No abstract available.


Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength.

Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM.

J Urol. 2000 Jan;163(1):187-90.


Urokinase-type plasminogen activator expression in human prostate carcinomas.

Van Veldhuizen PJ, Sadasivan R, Cherian R, Wyatt A.

Am J Med Sci. 1996 Jul;312(1):8-11.


Chylothorax: a complication of a left subclavian vein thrombosis.

Van Veldhuizen PJ, Taylor S.

Am J Clin Oncol. 1996 Apr;19(2):99-101.


Metoclopramide-induced sulfhemoglobinemia.

Van Veldhuizen PJ, Wyatt A.

Am J Gastroenterol. 1995 Jun;90(6):1010-1.


Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip.

Van Veldhuizen PJ, Neff J, Murphey MD, Bodensteiner D, Skikne BS.

Am J Hematol. 1993 Dec;44(4):243-8.


p53 expression in incidental prostatic cancer.

Van Veldhuizen PJ, Sadasivan R, Cherian R, Dwyer T, Stephens RL.

Am J Med Sci. 1993 May;305(5):275-9.


Evaluation of neoplastic spinal cord compressions.

Van Veldhuizen PJ, Stephens RL.

Kans Med. 1993 May;94(5):130-2. No abstract available.


Mutant p53 expression in prostate carcinoma.

Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL.

Prostate. 1993;22(1):23-30.


Takayasu arteritis presenting as retinal and vertebrobasilar ischemia.

Edwards KK, Lindsley HB, Lai CW, Van Veldhuizen PJ.

J Rheumatol. 1989 Jul;16(7):1000-2.


Supplemental Content

Loading ...
Support Center